13.74
Abcellera Biologics Inc Aktie (ABCL) Neueste Nachrichten
AbCellera to Report Third Quarter 2026 Financial Results on November 9, 2026 - Business Wire
AI Drug Discovery Forecasts Vary Widely as Sector Shifts to Deployment - marketscreener.com
Total equity of AbCellera Biologics, Inc. – HAN:8QQ - TradingView
JPMorgan Initiates AbCellera Biologics at Overweight With $17 Price Target - Moomoo
AbCellera Biologics, Inc. Actuals & Estimates (HAN:8QQ) - TradingView
Why Did IOVA, ABCL, CRWD Stocks Surge To 52-Week Highs Today? - TradingView
ABCL News | ABCELLERA BIOLOGICS INC (NASDAQ:ABCL) - ChartMill
J.P. Morgan Initiates AbCellera Biologics(ABCL.US) With Buy Rating, Announces Target Price $17 - Moomoo
ABCL Initiated Coverage By JP Morgan -- Rating Set to Overweight - GuruFocus
Why is Abcellera Biologics stock climbing today? By Investing.com - Investing.com Canada
Abcellera Biologics stock hits 52-week high at 13.23 USD - Investing.com
Why Did SLS, MRNA, ABCL Stocks Surge To 52-Week Highs Last Week? - Stocktwits
Goldman Sachs Initiates AbCellera Biologics(ABCL.US) With Hold Rating, Announces Target Price $13 - moomoo.com
ABCL Reinstated by Goldman Sachs -- Neutral Rating with Price Ta - GuruFocus
AbCellera Biologics Price Target Announced at $13.00/Share by Goldman Sachs - Moomoo
Goldman Sachs resumes AbCellera stock coverage with neutral rating - Investing.com
Goldman Sachs resumes AbCellera stock coverage with neutral rating By Investing.com - Investing.com Canada
ABCL Looks 201.0% Overvalued on GF Value™ - GuruFocus
AbCellera Biologics Inc. (ABCL) Options Chain - Yahoo Finance
ABCL Stock Price and Chart — NASDAQ:ABCL - tradingview.com
ABCL Stock Surges 121% in 3 Months: Here's What You Need to Know - Yahoo Finance
ABCL Should I Buy - Intellectia AI
AbCellera Biologics Inc. (ABCL) Stock Analysis: A Biotech Gem With A 34% Upside Potential - DirectorsTalk Interviews
Biotech Stocks At 52-Week HighsMNOV +36%, PBLS +10%, ABCL +9%, HAE, NEO - RTTNews
Abcellera Biologics stock hits 52-week high at 12.58 USD By Investing.com - Investing.com Australia
Abcellera Biologics stock hits 52-week high at 12.58 USD - Investing.com
Abcellera Biologics Inc (ABCL) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
AbCellera to present phase 2 data on menopause treatment drug By Investing.com - Investing.com Nigeria
ABCL Looks 171.0% Overvalued on GF Value™ - gurufocus.com
AbCellera Announces Presentation of Phase 2 Data for ABCL635 at the IMS World Congress on Menopause 2026 - Investing News Network
AbCellera to present phase 2 data on menopause treatment drug - Investing.com
AbCellera at Cantor healthcare conference: nk3r drug boosts hopes By Investing.com - Investing.com South Africa
AbCellera at Cantor healthcare conference: nk3r drug boosts hopes - Investing.com
AbCellera to Present at the Cantor Global Healthcare Conference on September 9, 2026 - Investing News Network
symbol__ Stock Quote Price and Forecast - CNN
Truist Financial Maintains AbCellera Biologics(ABCL.US) With Buy Rating, Maintains Target Price $30 - Moomoo
AbCellera Biologics (ABCL) Q4 2025 Earnings: Results, Market Reaction & History - 24/7 Wall St.
AbCellera Biologics Stock (ABCL) Opinions on Recent Surge and Insider Buying - Quiver Quantitative
Historical Data for AbCellera Biologics Inc. Tokenized Stock (Robinhood) in USD - CryptoRank
What'sGoing On With AbCellera Biologics Stock On Tuesday? - Benzinga
ABCL Stock Surges As ABCL635 Data Reset Wall Street Expectations - StocksToTrade
Are Medical Stocks Lagging ABCELLERA BIOLG (ABCL) This Year? - Eastern Progress
ABCL StockAbCellera Biologics Inc Stock Breaking News Today | ABCL Stock Price Punaises (dD09m2oJ3D) - Mshale
AbCellera Biologics (ABCL) Reports Phase 2 Success, Is It Still A Bargain? - simplywall.st
Abcellera director John S. Montalbano acquires common shares worth $110,300 - Bitget
AbCellera Biologics Director John S. Montalbano Acquires 10,000 Shares on August 18, 2026 - Kalkine Media
AbCellera Biologics | 4: Statement of changes in beneficial ownership of securities-Director Montalbano John S. - Moomoo
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):